TrialCardiovascular diabetology2017

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.

Ira Gantz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.